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Purpose: It is well accepted that conditions that cause central vision loss (CVL) have a negative 
impact on functional ability and quality of life (QoL), but the impact of diseases that cause 
peripheral vision loss (PVL) is less well understood. Focusing on glaucoma and age-related 
macular degeneration (ARMD), the effects of CVL and PVL on QoL were compared.
Methods: A systematic literature review of publications reporting QoL in patients with CVL 
or PVL identified 87 publications using four generic (Short-Form Health Survey-36 and -12, 
EuroQoL EQ-5D and Sickness Impact Profile) and five vision-specific (National Eye Institute 
Visual Function Questionnaire-51, -39, and -25, Impact of Vision Impairment and Visual 
Function-14) QoL instruments; 33 and 15 publications reported QoL in ARMD and glaucoma, 
respectively.
Results: QoL was impaired to a similar extent by diseases associated with PVL and CVL, but 
different domains were affected. In contrast to ARMD, mental aspects appeared to be affected 
more than physical aspects in patients with glaucoma.
Conclusions: The differential impact upon QoL might be a function of the pathology of the 
diseases, for example potential for blindness and better ability to perform physical tasks due to 
retention of central vision may explain these observations in glaucoma.
Keywords: vision loss, quality of life, glaucoma, age-related macular degeneration, diabetic 
macular edema, cataracts
Introduction
Visual impairment is a highly prevalent condition. In the US in 2000, nearly 1 million 
people over the age of 40 years were estimated to be blind and an additional 2.4 million 
had low vision.1 These numbers are projected to increase by approximately 70% over 
the next 12 years as the population ages.1
Age-related macular degeneration (ARMD), glaucoma and cataracts are the leading 
causes of blindness and low vision globally.1,2 ARMD and cataracts affect mainly 
central vision, although cataracts can also affect peripheral vision, while glaucoma 
has a larger impact on peripheral vision. The standard treatment for cataracts is 
surgery, which results in restored vision in more than 95% of patients, with minimal 
complications.3 ARMD and glaucoma, however, are currently incurable. Although 
there are existing treatments for ARMD and glaucoma, loss of vision associated with 
these two diseases is usually irreversible.
Vision loss and blindness have a negative impact on functional ability and 
quality of life (QoL).4,5 Patients with reduced QoL place a greater financial burden 
on healthcare systems and society than those with better QoL.6–10 Impairment of QoL Clinical Ophthalmology 2009:3 434
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in central vision loss (CVL) disorders, such as ARMD, 
is widely acknowledged,11–14 however, the impact on QoL 
of disorders that cause peripheral vision loss (PVL), such as 
glaucoma, is less well known. The objective of this study 
was to compare the QoL impact of PVL with that of CVL 
by reviewing the published literature. Specific focus was 
given retrospectively to glaucoma and ARMD because they 
are two key causes of severe PVL and CVL, respectively. 
In addition, glaucoma and ARMD are the most frequently 
described diseases in terms of QoL studies in the published 
literature in this area.
Methods
A systematic literature search was performed to identify 
publications that report QoL in patients with PVL and CVL. 
The Ovid search platform was used to search four databases: 
BIOSIS Previews, EMBASE, Cochrane Collaboration and 
MEDLINE. The search was performed on July 13th 2007 
and included publications indexed up to this date.
The search employed mapped terms for central vision 
and peripheral vision in EMBASE and MEDLINE. Search 
terms were related to vision (including ‘central vision’, 
‘peripheral vision’, ‘visual perception and fields’, ‘form, 
space and pattern recognition’, ‘fovea centralis’, ‘eye 
movements’), vision tests and disorders (‘visual acuity’, 
‘macular degeneration’, ‘choroidal neovascularization’), and 
‘quality of life’. The names of specific QoL instruments were 
not included as search terms, in order to capture all publica-
tions related to QoL in vision. The electronic search was 
supplemented by manual searching of the reference lists in 
each article to identify other relevant papers (eg, publications 
not indexed in the databases searched).
The search results were limited to publications that 
included one of the vision keywords and ‘quality of life’ 
and that used a generic or vision-specific QoL instrument; 
QoL instruments had to have reported results for more than 
one type of vision loss to allow comparison between PVL 
and CVL disorders. Disease-specific QoL instruments were 
excluded because they do not enable comparison between 
vision disorders.
The possibility of combining some, or all, of the results 
in the form of a meta-analysis was explored where several 
publications for a specific disorder according to a specific 
instrument were identified. However, given the high level 
of heterogeneity observed in terms of study population 
and design, it was decided not to conduct such an analysis. 
The weighted mean score was calculated by multiplying 
the average QoL score from each study by the number of 
patients in each study. The sum of these values was then 
calculated and divided by the total number of patients in 
all of the studies, to give the weighted mean average. The 
corresponding standard deviations (SD) were calculated by 
taking the square root of the variance from the weighted 
mean scores. This approach allowed comparisons between 
disorders without requiring results to be reported for each 
individual publication.
Results
A total of 87 unique publications were identified from the 
literature search. Four generic and five vision-specific QoL 
instruments reported the impact of vision loss on QoL 
(Table 1). Generic QoL instruments were Short-Form Health 
Survey (SF)-36, and -12, EuroQoL EQ-5D and Sickness 
Impact Profile (SIP).15–21 Vision-specific QoL instruments 
were National Eye Institute Visual Function Questionnaire 
(NEI-VFQ)-51, -39, and -25, Impact of Vision Impairment 
(IVI) and Visual Function (VF)-14.22–25
The 87 publications were broadly categorized accord-
ing to the main type of vision loss (peripheral or central) 
caused by the disease reported. Because many disorders 
of the eye are difficult to differentiate as affecting periph-
eral rather than central vision, or vice-versa, publications 
that were considered to be more strongly associated with 
PVL or CVL only are reported. Although choroideremia, 
retinitis pigmentosa and Usher syndrome were considered 
to be PVL disorders, no publications meeting criteria for 
inclusion in the study were identified that reported QoL 
in these disorders. Therefore, glaucoma publications 
accounted for all of those that could be classified as relat-
ing to QoL in PVL.
There were more publications examining QoL in patients 
with ARMD than any other vision disorder (33 publications; 
38%). Because glaucoma accounted for all the publications 
of QoL in PVL, and ARMD for the majority of publications 
in CVL, direct comparisons between the two disorders were 
made. Overall, a total of 45 publications reported QoL in 
glaucoma (n = 12), ARMD (n = 30), or both (n = 3). The 
breakdown of the publications identified as those reporting 
QoL in glaucoma and ARMD, by QoL instrument, is shown 
in Table 2.
The QoL impact of vision disorders is described for each 
instrument in the following two sections. Results comparing 
glaucoma with ARMD are reported first, followed by results 
comparing glaucoma with CVL disorders other than ARMD. 
If the study in question was an interventional study, then 
pre-intervention scores were used.Clinical Ophthalmology 2009:3 435
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Generic quality of life instruments
Short-Form Health Survey 36
Two publications reported QoL in glaucoma (both reported 
results from the same single study)12,13 and five reported QoL 
in ARMD.14,26–29
The two diseases had some similarities and some 
differences in the QoL domains on which they had an impact. 
The domains impacted most by glaucoma and ARMD 
were ‘vitality’, ‘general health’, ‘role limitations caused by 
physical problems’ and ‘role limitations caused by emotional 
problems’ (Table 3). Glaucoma appeared to have a greater 
impact on ‘vitality’, ‘mental health’, ‘bodily pain’ and ‘social 
functioning’ than ARMD. ARMD had a greater impact 
on ‘physical function’, ‘general health’, ‘role limitations 
caused by physical problems’ and ‘role limitations caused by 
emotional problems’ than glaucoma. Thus, whereas ARMD 
has a greater impact on the physical component of SF-36 
compared with glaucoma, glaucoma has a greater impact on 
the mental component compared with ARMD.
In diseases other than ARMD that are associated with 
CVL (cataracts,30–32 subfoveal choroidal neovascularization 
[SCNV],33 macular holes34 and keratoconus35), ‘role limita-
tions caused by physical problems’ and ‘general health’ 
(both part of the physical component of SF-36) were affected 
the most (weighted mean scores were 55–70 and 63–75, 
respectively).
One publication, the Ocular Hypertension Treatment 
Study,36 reported QoL using SF-36 in patients with ocular 
hypertension at moderate risk of developing primary open-
angle glaucoma. This study excluded patients with visual 
field loss and was therefore not included in our analysis of 
PVL disorders. However, patients’ QoL was affected by their 
condition. ‘Vitality’ (part of the mental component of SF-36) 
was the domain affected most, with a score of 69 (SD: 18).
Short-Form Health Survey 12
No publications were identified that reported the use of SF-12 
in glaucoma or any other PVL disorder. Four publications 
measured QoL in patients with ARMD using SF-12.37–40 
As with SF-36, CVL disorders, including ARMD and 
cataracts, had a greater impact on the physical component 
than the mental component of the SF-12 QoL questionnaire; 
ARMD weighted mean scores were 39.6 (SD: 3.6) vs 48.3 
(SD: 0.6), respectively.37-41
EuroQoL EQ-5D
One publication reported QoL in glaucoma according to the 
EQ-5D questionnaire42 and there were no publications for 
ARMD. Patients with glaucoma exhibited a similar degree 
of QoL impairment to those with cataracts (the only CVL 
disease studied using EQ-5D);43,44 mean scores were 0.80 
(SD: 0.23) and 0.76 (SD: 0.03), respectively.42–44
Sickness Impact Profile
Two publications reported SIP use in glaucoma45,46 but no 
publications used SIP in ARMD. In glaucoma, the psycho-
social domain was affected slightly more than the physical 
domain (scores 3.8 and 3.2, respectively).45,46 SIP total scores 
were slightly higher (QoL was worse) in patients with cata-
racts than in those with glaucoma (7.5–12.0 vs 3.4–5.2).45–48 
The cataract publications reported total scores only, therefore 
the effect on individual domains could not be analyzed.47,48
Vision-specific quality of life instruments
National Eye institute visual Function Questionnaire-51
Three publications reported QoL in glaucoma11–13 and two 
in ARMD11,14 (one publication reported on both glaucoma 
and ARMD11) according to NEI-VFQ-51.
Glaucoma and ARMD had some similarities and 
differences in the domains on which they had an impact 
(Table 4). The domains affected most by glaucoma were 
‘expectations’, ‘general health’, ‘general vision’ and 
‘peripheral vision’, with reported weighted mean scores 
of 48.3 (SD: 0.2), 67.3 (SD: 1.2), 66.3 (SD: 2.7) and 
Table 2 Glaucoma and age-related macular degeneration (ArMD) 
publications by quality of life instrument
Instrument Glaucoma 
publications (n)
ARMD 
publications (n)
SF-36 2 5
SF-12 0 4
EQ-5D 1 0
SiP 2 0
NEi-vFQ-51 3a 2a
NEi-vFQ-39 1 3
NEi-vFQ-25 8b 9b
ivi 1c 1c
vF-14 1 9
Total 19d 33
aOne publication reported both glaucoma and ArMD using NEi-vFQ-51.11
bOne publication reported both glaucoma and ArMD using NEi-vFQ-25.61
cOne publication reported both glaucoma and ArMD using ivi.76
dAmong the glaucoma publications, three publications reported more than one 
instrument: SF-36 and NEi-vFQ-51; 12 SF-36, NEi-vFQ-51 and  vF-14; 13 and NEi-vFQ-39 
and −25.51 Each incidence is shown against the relevant instrument, therefore the 
number shown here is 19 not 15, the number of unique publications.
Abbreviations: EQ, EuroQoL; ivi, impact of   vision impairment; NEi-vFQ, National 
Eye Institute   Visual Function Questionnaire; SF, short-form; SIP,  Sickness Impact Profile; 
vF,   visual Function.Clinical Ophthalmology 2009:3 437
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71.8 (SD: 3.1), respectively.11–13 ARMD had the greatest 
effect on ‘expectations’, ‘near activities’, ‘general vision’, 
‘driving’ and ‘distance activities’ (weighted mean scores 40.6 
[SD: 1.8], 47.5 [SD: 8.4], 49.0 [SD: 5.7], 50.3 [SD: 14.3] 
and 52.1 [SD: 12.2], respectively).11
While there were no publications reporting QoL in PVL 
using NEI-VFQ-51 other than in glaucoma, several publi-
cations reported QoL in CVL associated with cataracts,11 
optic neuritis49 and diabetic macular edema.50 As was the 
case with ARMD, the domain most affected by CVL in 
these diseases was ‘expectations’ (scores 47–66).11,49,50 The 
domains of ‘general health’ and ‘general vision’ were also 
affected in patients with these disorders (scores 57–72 and 
60–79, respectively).11,49,50
National Eye institute visual Function Questionnaire-39 
and -25
The NEI-VFQ-39 was used in one publication for glaucoma51 
and three publications for ARMD;52–54 the numbers of pub-
lications using NEI-VFQ-25 were 851,55–61 and 9,37,38,61–67 
respectively; one NEI-VFQ-25 publication reported QoL 
results in both glaucoma and ARMD.61
‘General health’, ‘mental health’ and ‘general vision’ 
were the domains affected most by glaucoma accord-
ing to NEI-VFQ-39, with scores of 54.2 (SD: 1.0), 57.8 
(SD: 3.9) and 62.6 (SD: 2.0), respectively.51 ‘General health’, 
‘general vision’ and ‘driving’ were affected most in ARMD 
(weighted mean scores were 72.0 [SD: 0.2], 74.1 [SD: 4.0] 
and 74.7[SD: 5.0]). In both disorders, ‘social functioning’ 
was affected the least (weighted mean score 84.8 [SD: 1.0] 
vs 94.2 [SD: 1.9] for glaucoma vs ARMD). This instrument 
showed that, in general, QoL was affected more severely by 
glaucoma than by ARMD. However, interpretation of the 
results for ARMD using NEI-VFQ-39 may be skewed by the 
weighting given to one large study53 which reported higher 
scores than most of the other smaller studies.
Similar patterns were observed in publications reporting 
the use of NEI-VFQ-25 (Table 5). ‘General health’ and 
‘general vision’ were affected most in glaucoma, with 
weighted mean scores of 47.6 (SD: 7.2) and 68.2 (SD: 7.9). 
‘Driving’, ‘general health’, ‘general vision’ and ‘near 
activities’ were affected most in patients with ARMD 
(weighted mean scores: 53.7 [SD: 38.2], 60.6 [SD: 9.0], 
61.4 [SD: 21.4] and 62.3 [SD: 27.8]). According to weighted 
mean scores, glaucoma appeared to have a greater impact on 
QoL than ARMD although, again, the data may be skewed 
by one large study in ARMD65 that reported higher scores 
than other studies. Indeed, in the publication that reported 
results for both diseases, ARMD appeared to have a greater 
impact on QoL than glaucoma:61 ‘general health’, ‘driving’, 
‘general vision’ and ‘mental health’ (scores of 43.6 [SD: 
19.11], 55.3 [SD: 49.9], 62.7 [SD: 19.11] and 68.8 [SD: 24.1], 
respectively) were significantly affected in glaucoma (n = 69) 
compared with the reference group. In ARMD (n = 78), all 
domains apart from ‘peripheral vision’, ‘color vision’ and 
‘ocular pain’ were significantly affected compared with the 
reference group; the domains affected most were ‘driving’, 
‘near activities’, ‘distance activities’, ‘mental health’, ‘role 
difficulties’, ‘general vision’ and ‘general health’ (scores 
of 12.8 [SD: 45.9], 38.6 [SD: 27.4], 40.0 [SD: 28.3], 37.1 
[SD: 27.4], 38.4 [SD: 28.3], 41.2 [SD: 20.3] and 45.7 [SD: 
20.3], respectively).
The NEI-VFQ-39 and -25 data were similar to those 
from the NEI-VFQ-51 instrument for diseases associated 
with CVL other than ARMD (NEI-VFQ-39: cataracts41 
and SCNV;68–70 NEI-VFQ-25: cataracts,61 central reti-
nal vein occlusion,71 macular holes,34,72 optic neuritis73 
and keratoconus)74,75. According to the NEI-VFQ-39 
and -25 questionnaires, the QoL impact of non-ARMD 
CVL disorders followed a similar pattern to that seen for 
ARMD. ‘General vision’, ‘driving’ and ‘near activities’ 
were affected most in non-ARMD CVL disorders accord-
ing to NEI-VFQ-39 (weighted mean scores of 53.2–59.5, 
44.3–58.8 and 56.6–65.4); ‘general vision’, ’driving’ 
and ‘general health’ were affected the most accord-
ing to NEI-VFQ-25 (scores 54.1–87.6, 46.0–91.4 and 
46.9–83.0). ‘Expectations’ was the domain most affected 
in non-ARMD CVL according to NEI-VFQ-51; however, 
this domain is not included in the NEI-VFQ-39 and -25 
questionnaires.
Table 3 Short-form-36 scores for glaucoma12,13 and age-related 
macular degeneration (ArMD)14,26–29
Domain Glaucomaa 
Mean (SD)
ARMDa 
Mean (SD)
Bodily pain 72.7 (25.4) 75.5 (6.0)
General health 69.7 (21.4) 64.5 (6.5)
Mental health 72.9 (19.7) 74.7 (3.3)
Physical function 70.6 (28.6) 68.2 (17.0)
role limitation 
by physical problems
66.4 (40.3) 55.1 (25.4)
role limitation 
by emotional problems
69.8 (39.9) 65.7 (30.0)
Social functioning 80.9 (23.4) 87.3 (6.5)
vitality 57.8 (18.4) 60.2 (3.2)
aweighted average across studies.Clinical Ophthalmology 2009:3 438
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impact of vision impairment
One publication reported the use of the IVI questionnaire 
in patients with glaucoma or ARMD.76 Glaucoma affected 
QoL to a greater extent than ARMD in all domains except 
for ‘social interaction’ (scores were 1.93 [SD: 0.98] vs 1.63 
[SD: 0.92], 2.38 [SD: 1.12] vs 1.77 [SD: 1.04], 1.77 [SD: 
1.04] vs 1.50 [SD: 0.61], 1.18 [SD: 0.49] vs 0.92 [SD: 0.34], 
and 2.79 [SD: 1.32] vs 2.87 [SD: 0.76] for ‘emotional reaction 
to vision loss’, ‘leisure’, ‘mobility’, ‘household’ and ‘social 
interaction’ domains, respectively) (Table 6). There were 
no publications reporting QoL in vision disorders other than 
glaucoma or ARMD using the IVI questionnaire.
visual Function-14
The QoL in glaucoma was investigated in one publication13 
and in ARMD in nine publications14,26,28,77–82 using VF-14. The 
weighted mean values calculated for the ARMD scores were 
slightly lower than those for glaucoma (score: 69.7 [SD: 14.6] 
vs 79.1 [SD: 21.8]), although it is important to consider the 
differences in sample size: a small sample of patients with 
glaucoma (n = 147) compared with ARMD (n = 1307).
The only other vision disorder that was identified as 
having been studied using VF-14 was cataracts,47,48,66,79,83–89 
for which the weighted mean score was similar to glaucoma 
and ARMD (score: 74.6 [SD: 7.9]).
Discussion
Our systematic literature search has shown that diseases 
associated with PVL and CVL have a negative impact on 
QoL. Reviewing results from both vision-specific and generic 
QoL instruments has allowed us to investigate patients’ 
perceptions of visual function, in addition to the influence of 
their visual disability on more general aspects of QoL, such 
as emotional well being and social functioning.
Generic quality of life instruments
Glaucoma vs ArMD
A relatively consistent finding with generic QoL instruments 
was that glaucoma and ARMD appeared to have an 
impact upon different QoL domains, although a lack of 
data prohibited comparisons between the two diseases by 
SF-12 (no glaucoma publications), EQ-5D and SIP (no 
ARMD publications) results. Overall, in glaucoma, mental 
components were affected to a greater degree than physical 
components, whereas the opposite was true for ARMD. 
In most QoL domains of the SF-36, however, the differ-
ence between the impact of the two diseases was slight and 
unlikely to be clinically significant. The largest differences 
in SF-36 scores occurred in the ‘role limitations caused by 
physical problems’, ‘general health’ and ‘social functioning’ 
(scores were 11.3 points lower for ARMD vs glaucoma, 
5.2 points lower for ARMD vs glaucoma, and 6.4 points 
lower for glaucoma vs ARMD, respectively). All other 
domains had a difference of four points or less. A possible 
explanation for this lack of difference between diseases may 
be because the SF-36 (and therefore the SF-12, which is based 
on the SF-36 instrument), by design, does not adequately 
measure functional visual impairment in glaucoma.90,91 
It is also difficult to draw strong conclusions from the SF-36 
data because this instrument was used in only one study (two 
publications) in glaucoma.
Glaucoma vs non-ArMD CvL disorders
Wider comparison between diseases affecting central and 
peripheral vision was not possible as our search found no 
suitable QoL studies for PVL diseases other than glaucoma. 
However, SF-36 and SF-12 data supported the greater impact 
of CVL on physical components than mental components. 
According to the SF-36, ‘role limitations caused by physical 
problems’ and ‘general health’ were the domains affected the 
most in patients with the CVL disorders cataracts, SCNV, 
macular holes and keratoconus.
Other than ARMD, cataract was the most frequently-
reported CVL disorder in terms of QoL publications. Similar 
results were seen for cataracts with the SF-12 as were seen 
Table 4 Effects of glaucoma and age-related macular degeneration 
(ArMD) on quality of life using the National Eye institute visual 
Function Questionnaire (NEi-vFQ)-51 instrument11–14
Glaucoma ARMD
Weighted 
mean (SD)
Weighted 
mean (SD)
N 225 193
General health 67.3 (1.2) 62.6 (8.3)
General vision 66.3 (2.7) 49.0 (5.7)
Ocular pain 81.7 (5.3) 91.5 (5.1)
Near activities 75.6 (3.9) 47.5 (8.4)
Distance activities 76.3 (4.9) 52.1 (12.2)
Social functioning 86.8 (3.0) 71.3 (7.5)
Mental health 72.6 (6.1) 64.3 (1.4)
Expectations 48.3 (0.2) 40.6 (1.8)
Role difficulties 79.2 (5.7) 56.9 (8.0)
Dependency 85.9 (5.2) 65.2 (10.0)
Driving 75.0 (5.1) 50.3 (14.3)
Color vision 89.6 (2.5) 74.1 (12.3)
Peripheral vision 71.8 (3.1) 59.8 (19.4)Clinical Ophthalmology 2009:3 439
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with the SF-36. Results using EQ-5D showed that the overall 
levels of impairment suffered by patients with glaucoma was 
very similar to patients with cataracts, whereas SIP suggested 
that QoL was worse in the latter group. For glaucoma, the 
psychological domain was affected slightly more than 
the physical domain, with a small and probably clinically 
irrelevant difference of 0.6 points. However, because only 
SIP total scores were available for patients with cataracts, 
there was no opportunity to assess the potential differential 
impact on the domains of this instrument caused by the two 
conditions.
Overall, the results from generic instruments showed a 
difference in the types of aspects of QoL that are affected 
by glaucoma compared with ARMD; mental more than 
physical in glaucoma, and vice-versa for ARMD. This 
may be explained by the differences in the pathology of the 
diseases. Glaucoma may have less of an inhibitory effect on 
patients’ ability to perform physical day-to-day tasks because 
their central vision is not affected substantially, but patients 
may worry about the future impact of their disease on their 
vision (potential for blindness); ARMD patients, however, 
may be less able to perform the physical tasks than patients 
with glaucoma, because of CVL. Vitality and general health 
were affected substantially in both diseases, indicating that 
patients have reduced energy levels and perceive that their 
personal health is poor and likely to get worse.
Vision-specific quality of life instruments
Glaucoma vs ArMD
Results using vision-specific QoL instruments also showed 
some similarities and differences between glaucoma and 
ARMD. Across the three NEI-VFQ instruments, ‘expectations’, 
‘general health’, ‘general vision’ and, as expected, ‘peripheral 
vision’ were affected most in glaucoma, while ‘expectations’, 
‘near activities’, ‘general vision’ and ‘driving’ were affected 
the most in ARMD. It is interesting that ‘expectations’ is the 
domain affected most in both diseases. Although patients 
diagnosed with glaucoma or ARMD often already have 
some knowledge about their disease before being invited 
to participate in a QoL study, this knowledge may not be 
accurate and lead to low expectations. Ultimately, a lack 
of patient education about glaucoma and ARMD may be 
a key factor in the low expectation. For example, although 
many patients are aware of the lack of an effective treatment 
for restoring vision loss, most are unaware that surgical 
procedures are available for glaucoma. Most patients think 
that having glaucoma or ARMD will eventually lead to 
blindness. However, the majority of patients with glaucoma 
and ARMD continue to have functional vision throughout 
their lifetimes. Nevertheless, even a remote chance of blind-
ness is a huge burden to the patient because of the importance 
of visual function, and because of the chronic nature of the 
disease. Patients should be educated about the potential 
benefits of early diagnosis and appropriate management of 
glaucoma or ARMD in reducing the chance of severe vision 
loss and blindness.
The publications we identified appeared to show that 
QoL is worse in ARMD than in glaucoma; however, only 
one VF-14 study in glaucoma (147 patients) was identified 
compared with nine in ARMD (1307 patients), limiting our 
interpretation of these findings. Similarly, only one study 
reported IVI data for glaucoma and ARMD; thus, the finding 
that glaucoma was associated with slightly worse QoL than 
ARMD in all domains apart from ‘social interaction’ and 
that, contrary to the results from other instruments, ‘social 
interaction’ was affected most in both diseases, cannot be 
generalized.
Non-ArMD CvL disorders
No suitable QoL studies for PVL diseases other than 
glaucoma were found that used vision-specific QoL 
instruments. Studies of non-ARMD CVL disorders included 
optic neuritis and diabetic macular edema, but the majority 
focused on cataracts.
These studies confirm a significant impact on the 
‘expectations’, ‘general vision’ and ‘general health’ domains 
of NEI-VFQ in patients with CVL disorders. For cataracts 
specifically, ‘expectations’, ‘general vision’, ‘driving’, ‘near 
activities’ and ‘general health’ were affected the most accord-
ing to vision-specific QoL instruments, which was consistent 
with the physical limitations caused by cataracts and patients’ 
curative expectations of cataract surgical procedures.
The finding that ‘general health’ was affected 
negatively in patients with diabetic macular edema or 
optic neuritis was expected; however, the large impact of 
cataracts on this domain was more surprising and poses 
the question of whether this is due to the cataract itself or 
to poor health associated with older age. One publication 
explored the relationship between visual acuity impair-
ment and eye disease on NEI-VFQ-25 scores in Hispanic 
adults aged 40 years.92 After adjusting for visual acuity, 
the negative effect of cataracts on QoL was no longer 
significant in any NEI-VFQ-25 domain except ‘driving’, 
suggesting that loss of vision could be responsible for the 
majority of the QoL deficits in this patient population.92 
This publication was not included in our study because Clinical Ophthalmology 2009:3 440
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changes in scale rather than absolute scores only were 
reported, preventing direct comparison with results 
reported in other publications.
Overall, the results from the vision-specific QoL 
instruments appear to relate more directly to the type of 
vision loss associated with each disease than results using 
generic QoL instruments: glaucoma affected peripheral 
vision whereas ARMD had more of an impact on driving 
and near and distance activities.
recent studies
Among articles published since we conducted our 
systematic review, one publication reported the use 
of SF-12 and VF-14 in patients with visual disorders, 
including glaucoma and ARMD.90 In ARMD, but not glau-
coma, a decrease in visual impairment was correlated with 
reduced QoL according to both instruments.90 However, 
the authors acknowledge that the usefulness of the SF-12 
(as a derivative of the SF-36) and the VF-14 for adequately 
capturing functional visual impairment in glaucoma is 
limited. The VF-14 lacks the ability to measure visual field 
defect and color vision, which are important indicators in 
glaucoma.91
The NEI-VFQ-25 was used to assess the relationship 
between depression and vision-related QoL in patients with 
PVL caused by retinitis pigmentosa, and demonstrated that 
patients with depression and PVL had poorer vision-related 
outcomes.93 Patients in this study had lower QoL than the 
glaucoma group in our review on all subscales bar ocular 
pain (RP [non-depressed patients only]: 76.8 vs glaucoma 
75.1) and had lower QoL scores on all subscales than those 
with ARMD.
Studies in patients with homonymous visual field 
defects (HVFDs) also showed that they had lower 
NEI-VFQ-25 scores compared with healthy individuals.94 
In general, patients with HVFDs had a better QoL on the 
subscales, but had a lower QoL with regard to general 
health (44.7), driving (32.6) and peripheral vision (69.7) 
compared with patients identified in this review with either 
glaucoma or ARMD. The latter two results are consistent 
with expectations, since patients with HVFDs are known 
to find any activity requiring peripheral vision to be 
highly problematic. They also had slightly lower QoL on 
the general vision subscale than patients with glaucoma 
(65.6 vs 68.2).
The NEI-VFQ-39 has also been used to asses vision-
related QoL in cerebrally damaged patients undergo-
ing vision restoration training, and showed that scores 
increased in response to treatment.95 These patients had 
a poorer QoL on all subscales when compared with the 
ARMD patients reviewed in this study using the same 
instrument, but had better QoL than glaucoma patients 
on four subscales: ocular pain, distance vision, mental 
health and color vision. However, as the author notes, 
unless the differences between groups are 10 points 
then the differences are not perceived to be clinically 
meaningful. Using this definition, the differences between 
brain-injured patients and ARMD patients are clinically 
meaningful on all subscales, with the exception of ocular 
pain and color vision, and the differences compared with 
glaucoma patients are clinically meaningful on five sub-
scales (ocular pain, role difficulties, driving, color vision 
and peripheral vision).
Another study using the NEI-VFQ-39 found that visual 
field loss and visual acuity correlated significantly with 
vision-related QoL (assessed by NEI-VFQ) but not with 
health-related QoL (assessed by SF-36) in brain-injured 
patients.96 Comparing the results of this study with those 
found in our review, we found that brain-injured patients 
had lower QoL scores on all subscales compared with 
ARMD patients, and these were clinically meaningful in 
all cases, with the exception of ocular pain. Compared with 
glaucoma patients, scores were lower on all subscales, with 
the exception of ocular pain, mental health and color vision; 
Table 5 Effect of glaucoma and age-related macular degeneration 
(ArMD) assessed using the National Eye institute visual Function 
Questionnaire (NEi-vFQ)-25 instrument37,38,51,55–67
Glaucoma ARMD
Weighted 
mean (SD)
Weighted 
mean (SD)
N 878 1775
General health 47.6 (7.2) N = 1655 60.6 (9.0)
General vision 68.2 (7.9) 61.4 (21.4)
Ocular pain 75.1 (11.3) 88.5 (3.1)
Near activities 76.6 (7.8) 62.3 (27.8)
Distance activities 79.2 (7.5) 65.6 (25.1)
Social functioning 88.8 (5.9) 79.7 (21.3)
Mental health 70.0 (30.5) 67.3 (21.8)
Role difficulties 73.4 (10.9) 67.6 (25.5)
Dependency 82.4 (13.3) 75.2 (26.9)
Driving 73.1 (9.1) 53.7 (38.2)
Color vision 91.4 (3.9) 83.8 (14.9)
Peripheral vision 80.1 (8.0) 83.4 (14.7)
Mean composite score N = 1482 75.9 (8.0) N = 1617 75.1 (18.1)Clinical Ophthalmology 2009:3 441
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however the differences were clinically meaningful only 
with respect to ocular pain, role difficulties, driving and 
peripheral vision.
Three recent studies have described the burden of 
neovascular ARMD (NV-ARMD) on patient-reported 
functioning.10,97,98 NV-ARMD represents 10% to 15% 
of all ARMD and accounts for 90% of ARMD-related 
severe vision loss. All three studies showed significantly 
lower NEI-VFQ-25 summary scores in patients with 
NV-ARMD compared with individuals without ARMD.10,97,98 
NEI-VFQ-25 summary scores (range 48.0–52.7) were 
similar to those seen in the studies included in our review. 
In general, an association between reduced visual acuity and 
decreased NEI-VFQ-25 composite scores and in individual 
domains was observed.10,97,98 EQ-5D scores, however, were 
significantly lower in patients with NV-ARMD compared 
with controls in the largest multinational study only,98 
and generally did not correlate with visual acuity. These 
findings support those of another study in ARMD99 and 
suggest that EQ-5D is not a suitable measure of QoL in 
this population.
Choosing a QoL instrument
When assessing vision disorders, the choice of QoL 
instrument should be influenced by whether comparisons 
with other disorders are to be made. QoL instruments are 
available for specific diseases; however, their utility is 
restricted to evaluating patients with the disease against con-
trol or reference individuals only. Unlike QoL instruments 
suitable for visual diseases on a more general level, they do 
not enable comparisons with other sight disorders.
We included vision-specific or generic instruments only 
in our study to allow comparisons between vision disorders. 
Generic instruments can be used to make comparisons across 
a wide range of diseases, whether vision-related or not. 
However, they lack the sensitivity of vision-specific QoL 
instruments. We found that vision-specific instruments were 
used more frequently than generic instruments in glaucoma 
and CVL diseases. The NEI-VFQ instruments were used 
most frequently overall, and the VF-14 questionnaire was 
used more often in ARMD than glaucoma. SF-36 was the 
most commonly used generic instrument. Although the 
EQ-5D is a highly useful tool for calculating health utilities 
that can easily be translated into health economics statistics, 
the lack of studies using this instrument can perhaps be 
explained by its poor sensitivity to the impact of loss of vision 
on activities of daily living.99
The authors of a recent review of the relative useful-
ness of QoL instruments in studying glaucoma concluded 
that there was not an accepted ‘industry standard’ tool, 
although they recommended NEI-VFQ instruments as a 
standard comparator, based mainly on their ease of use.91 
The SF-36 instrument is well validated and easy to use, but 
lacks correlation with visual acuity measures.91 Similarly, 
the SIP instrument lacks sensitivity for visual impairment; 
its domains are only weakly correlated with visual acuity 
or visual field status.91 The NEI-VFQ-51 instrument may 
be more sensitive than SF-36, but it takes a relatively long 
time to complete. The NEI-VFQ-25 instrument takes less 
time to complete than NEI-VFQ-51 but lacks visual field 
consideration compared to more specific glaucoma tools, 
such as the Glaucoma Quality of Life 15 scale100 and the 
Symptom Impact Glaucoma Score.45 The authors of the 
review also suggested that some of the vision-specific 
instruments focus on physical rather than social or personal 
aspects of QoL, and therefore these latter aspects are often 
not fully assessed.91 As we have seen, this contrasts with 
the generic instruments, which show a greater impact of 
glaucoma on mental rather than physical aspects of QoL, 
and vice-versa for ARMD. A possible reason for our 
observations could be that, in patients with early stages 
of glaucoma (in whom there is minimal functional impair-
ment), worry about blindness could affect mental QoL, 
while physical aspects of QoL remain relatively unaffected. 
Table 6 Effects of glaucoma and age-related macular degeneration (ArMD) on quality of life assessed using the impact of vision 
impairment instrument9,76
Study N Emotion Leisure Mobility Social Household
Glaucoma
  Mean score 11 1.93 2.38 1.77 2.79 1.18
  SD 0.98 1.12 1.04 1.32 0.49
ArMD
  Mean score 37 1.63 1.77 1.50 2.87 0.92
  SD 0.92 1.04 0.61 0.76 0.34Clinical Ophthalmology 2009:3 442
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This worry may be compounded by a lack of understanding 
or education about the disease, the absence of a curative 
treatment, and having to undergo chronic medical or surgi-
cal therapy with frequent follow-up visits as a reminder of 
living with a potentially blinding disorder.
Study limitations
A possible limitation of our study is that we did not 
search specific disease terms; the inclusion terms such as 
‘glaucoma’ and ‘ARMD’ in addition to the general terms 
‘central vision loss’ and ‘peripheral vision loss’ may have 
identified additional publications for review. However, 
the decision to compare glaucoma with ARMD was made 
following generation and analysis of the search results, 
once it became clear that these two diseases were the 
most published in terms of QoL studies in PVL and CVL, 
respectively. Nevertheless, the search generated a sufficient 
number of publications to enable us to make comparisons 
between peripheral and central vision loss disorders for 
most of the QoL instruments. Classification of the diseases 
into distinct CVL and PVL types presented a significant 
challenge. Because many disorders of the eye are difficult 
to differentiate as affecting peripheral rather than central 
vision, or vice-versa, only diseases that were considered 
to be more strongly associated with PVL or CVL were 
included. Papers that reported patients with ‘visual field 
loss’ only were not included. As already discussed, for 
some QoL instruments a lack of data in either glaucoma 
or ARMD means that some of the results should be viewed 
with a degree of caution.
Conclusion
Diseases associated with PVL, such as glaucoma, and CVL, 
such as ARMD, have a negative impact on QoL and appear to 
impact on different QoL domains. A greater impact on mental 
aspects of QoL was consistently found for PVL disorders, and 
on physical aspects for CVL disorders. Both disorders affected 
patients’ expectations of treatment and their general vision. 
The impact of CVL has often been thought to have a greater 
impact on patients’ QoL than PVL. We have found the impact 
to be comparable between PVL and CVL. As the population 
ages, the prevalence of vision disorders is set to rise, therefore 
it will become even more important to consider the impact of 
reduced QoL on patients, healthcare systems and society.
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